Search

Byline: Daily Record Staff Rockville-based biotech company Rise Therapeutics Wednesday announced it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National [...]

Byline: Steven Goff Russell Canouse no longer worries about needing to pull over to find a restroom while driving his 2-year-old son Christian to day care. Painful flare-ups have faded. [...]

Byline: CARSON FIELD As a four-year starter on Sierra's football team, Ruben Valenzuela hasn't let anything get in the way of his development not even a serious disease. Valenzuela, a [...]

- Work builds upon prior MIIST305 development in radiation mitigation and ulcerative colitis - CLAREMONT, Calif. -- Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today [...]

Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis [...]

TP-317, an Oral BLT1 Agonist, was Well Tolerated, Showed a Favorable Safety Profile, and Demonstrated Target Engagement A Phase 1b Study of TP-317 in Ulcerative Colitis Patients is Planned for [...]

ROCKVILLE, Md., Oct. 23, 2024 /PRNewswire/ -- Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the [...]

Transaction is highly shareholder value accretive, enabling the potential acceleration of the global registration directed Phase 3 program in ulcerative colitis, the Phase 2 program in Crohn's disease, and additional [...]

Tulisokibart is now being evaluated in two Phase 3 studies in ulcerative colitis and Crohn's disease 12-week data from the Phase 2 ARTEMIS-UC trial recently published in the New England [...]

GHENT, Belgium -- MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Gregoire Franoux, M.B.A., to the newly [...]

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program PALI-2108, [...]

HONG KONG, Sept. 4, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong Kong Baptist University (HKBU) has achieved a significant milestone in developing a [...]

M2 EQUITYBITES-November 4, 2024-OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Monday announced positive results from the [...]

M2 EQUITYBITES-October 28, 2024-NImmune Biopharma Acquires Development and Commercialisation Rights to Omilancor to Accelerate Phase 3 Protocols in Asian Markets (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk US-based late-clinical-stage precision inflammation and immunology [...]

M2 EQUITYBITES-September 25, 2024-Alvotech launches confirmatory study for Entyvio biosimilar (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biotech company Alvotech S.A. (NASDAQ:ALVO) announced on Wednesday that it has initiated a confirmatory patient study [...]

CAMBRIDGE, United Kingdom, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce [...]

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing [...]

- Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end - Based on the modeling and simulations, Palisade [...]

Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist Top-line data accelerated and now anticipated [...]

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for 'Gut Microbiota Bioactivated PDE4 Inhibitor Precursors' with similar structure to PALI-2108 and PALI-1908 [...]

Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 [...]

Presentation in Boston at 9th Microbiome Movement Drug Development Summit, 10-12 July 2024 CAMBRIDGE, UK , July 09, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of [...]

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=d_s0Y4Z8KCoSYJCFAw-FaD8c_A139VNKFxJOEJ0TllyIa_GNtFlv26UousGbgny_1zXWJF_nSe0lsZd0Du-vd0M5cSdaGEKKHClBn9-a5CnaUC4D6RVtgpR7nAXiNBCm (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, [...]

Second Prestigious BMC Grant in Under a Year will Enable Creation and Validation of Biomarker-Driven Process for Precisely Selecting Patients Most Likely to Respond to GPR35 Inhibition Company Narrows Initial [...]

Drug-device combination leverages Biora's NaviCap (TM) platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, [...]

Portfolio of Oral Selective α4B7 Inhibitors Acquired from EA Pharma, Eisai's GI Subsidiary Phase 2 Clinical Program in Ulcerative Colitis to Start in First Half of 2025 with Lead Asset [...]

Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,[sup.1] and a 52-week maintenance study, [...]

EXTON, PA, June 12, 2024 (GLOBE NEWSWIRE) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie's Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative [...]

Byline: Ian Sample Jun 05, 2024 (The Guardian - ABIX via COMTEX) -- It is estimated that more than seven million people worldwide have inflammatory bowel disease, whose two main [...]

Byline: Jon Asplund AbbVie is adding to its pipeline of drugs for inflammatory and autoimmune diseases with an agreement to buy Landos Biopharma, a clinical stage biopharmaceutical company that's developing [...]

M2 EQUITYBITES-July 26, 2024-AbbVie receives EU approval for SKYRIZI in ulcerative colitis (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Pharmaceutical research & development company AbbVie (NYSE:ABBV) on Friday announced European Commission approval for [...]

2024 JUL 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 [...]

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative [...]

Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital and existing investors aMoon Fund and Blackstone Multi-Asset Investing, among other [...]

Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P Rapid Onset of Efficacy and Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, [...]

- Recent safety and efficacy data in both Ulcerative Colitis and Pouchitis continue to support MH002's potential in indications characterized by mucosal damage and inflammation. GHENT, Belgium -- MRM Health [...]

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b [...]

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST - [...]

- Parallel programs will advance MIIST305 in ulcerative colitis (UC) and gastrointestinal acute radiation syndrome (GI-ARS) - Phase 1 clinical studies expected to begin in 2025 CLAREMONT, Calif. -- Synedgen, [...]